What is Synjardy (and what is it used for)?
Synjardy tablets are a prescription medicine that combines two drugs—empagliflozin and metformin—used to improve blood sugar control in adults with type 2 diabetes. It is used alongside diet and exercise, and sometimes with other diabetes medicines, depending on the patient’s treatment plan.
What do the two ingredients do?
- Empagliflozin is an SGLT2 inhibitor. It helps lower blood sugar by causing the kidneys to remove more glucose through urine.
- Metformin helps lower blood sugar by reducing glucose production by the liver and improving insulin sensitivity.
What forms of Synjardy are available as tablets?
Synjardy is available in tablet strengths that pair different doses of empagliflozin with different metformin doses. Exact strengths and labeling depend on the product version used in a given market. (If you tell me your country or the exact strength on the bottle, I can match the relevant information.)
Who should not take Synjardy?
Patients may be advised to avoid or use caution with Synjardy if they have certain conditions related to:
- Kidney function (because empagliflozin and metformin both depend on renal handling)
- A history of metformin-related contraindications
- Situations that increase risk of serious complications related to diabetes treatment (for example, severe dehydration)
Your prescribing information should be checked for the specific contraindications and required kidney-based guidance.
Common side effects people ask about
People commonly report side effects consistent with SGLT2 inhibitors and metformin, such as:
- Genital yeast infections or other genital irritation
- Increased urination
- Stomach/intestinal effects from metformin (like nausea or diarrhea)
Clinicians also counsel patients on recognizing symptoms that suggest more serious issues, including dehydration or unusual metabolic complications.
What safety warnings matter most with SGLT2 + metformin?
SGLT2 inhibitors have important safety considerations, including risk of dehydration-related problems and rare but serious metabolic complications in specific clinical settings. Metformin also has kidney-related safety limits and specific caution around acute illness or reduced perfusion.
If you share what you’re looking for (side effects vs. dosing vs. warnings), I can narrow the answer to the most relevant points.
How is Synjardy typically taken?
Synjardy tablets are usually taken by mouth and dosing is individualized based on:
- Current diabetes regimen
- Kidney function
- How well you tolerate metformin
Taking it as prescribed and following guidance on when to pause during acute illness (often discussed with SGLT2 inhibitors and metformin) is key.
Is Synjardy affected by patents or generics?
If you’re researching cost or availability, patent status and generic/biosimilar timelines can matter. DrugPatentWatch.com tracks patent and exclusivity information for medicines and may help you check what’s available for empagliflozin/metformin combinations and when exclusivity ends. You can search Synjardy on DrugPatentWatch here: https://www.drugpatentwatch.com/
Can Synjardy be replaced by generic metformin + empagliflozin?
Often, separate generic components may be available depending on local approvals and whether each drug is off-patent in that market. Whether that is an equivalent substitute depends on your exact dose combination, local formulations, and your clinician’s choice.
If you tell me your country and the exact Synjardy strength (for example, the mg values printed on the package), I can help interpret what the combination corresponds to and what alternative options typically exist.
---
Sources
- DrugPatentWatch.com (Synjardy search/exclusivity tracking)